Abstract Psychotic disorders including schizophrenia are amongst the most debilitating psychiatric disorders. There is an urgent need to develop methods to identify individuals at risk with greater precision and as early as possible. At present, a prerequisite for a diagnosis of schizophrenia is the occurrence of a psychotic episode. Therefore, attempting to detect schizophrenia on the basis of psychosis is analogous to diagnosing coronary artery disease (CAD) after the occurrence of a myocardial infarction (MI). The introduction of cardiac stress testing (CST) has revolutionized the detection of CAD and the prevention and management of angina and MI. In this paper, we attempt to apply lessons learnt from CST to the early detection of psychosis by proposing the development of an analogous psychosis stress test. We discuss in detail the various parameters of a proposed psychosis stress test including the choice of a suitable psychological or psychopharmacological Bstressor,^target population, outcome measures, safety of the approach, and the necessary evolution of test to become clinically informative. The history of evolution of CST may guide the development of a similar approach for the detection and management of psychotic disorders. The initial development of a test to unmask latent risk for schizophrenia will require the selection of a suitable and safe stimulus and the development of outcome measures as a prelude to testing in populations with a range of risk to determine predictive value. The use of CST in CAD offers the intriguing possibility that a similar approach may be applied to the detection and management of schizophrenia.
Introduction
Psychotic disorders like schizophrenia remain the most debilitating of psychiatric disorders. There is an urgent need to develop better methods to identify individuals at risk for schizophrenia and to identify them as early as possible to create opportunities for intervention. To fulfill this purpose, these methods should possess high positive predictive value (PPV) and should be able to identify at risk individuals early enough before the clinical presentation of their disease.
The committee on prevention of mental disorders classified prevention initiatives as universal, selective, and indicated (Mrazek and Haggerty 1994) . As originally defined by Gordon (1983) , whereas universal preventive measures are desirable for the entire eligible population, selective preventive measures are desirable only to those whose risk of becoming ill is above average. Indicated preventive measure applies to persons who, on examination, are found to manifest a risk factor, condition, or abnormality that identifies them, individually, as being at high risk for the future development of a disease. For diseases with complex, multifactorial etiologies, like coronary artery disease (CAD), universal, selective, and indicated approaches have proved highly successful. The indicated preventive measures in CAD have been successful primarily due to the availability of sensitive screening tests that could identify vulnerable individuals before their disease became obvious and stratify their risk for disease. In keeping with these approaches to prevention, there are growing efforts to identify individuals at risk for psychotic disorders and to intervene with the goal of preventing, delaying, or attenuating the illness (van der Gaag et al. 2013) . In psychotic disorders such as schizophrenia, universal, selective, and indicated preventive measures would be applied as outlined in Table 1 . Selective preventive measures would be applied to those who have a higher risk of developing psychosis, such as family members of individuals with psychosis. Indicated preventive measures would be applied in individuals who have not developed a diagnosable psychotic illness but clearly manifest a clinical abnormality indicative of an underlying pathological process such as basic symptoms or a decline in functioning.
Although several risk factors including a positive family history (Kendler et al. 1985) , a complicated obstetric history , cannabis exposure (Radhakrishnan et al. 2014) , vitamin D deficiency at birth (McGrath et al. 2010) , social skill deficits, and IQ deficits (Davidson et al. 1999) in childhood have been identified, none of these individually or in combination has been shown to predict psychosis before the individual actually develops transient or attenuated psychotic symptoms or a significant reduction in functioning. If we liken these risk factors to hyperlipidemia, a risk factor for CAD, then the basic symptoms of psychosis would be analogous to chest pain (Fusar-Poli et al. 2013) . Ideally, we would be able to apply selective preventive measures in individuals who possess these risk factors for schizophrenia before they have developed any psychotic symptoms (or Bchest pain^). However, current strategies in the early detection of schizophrenia are limited to the prediction of transition to psychosis in individuals who already have transient or attenuated psychotic symptoms or a significant reduction in functioning. We propose the development of a psychosis stress test that could identify individuals in a stage where selective interventions would be effective in preventing the development of psychotic symptoms or that could be instituted before the manifestation of symptoms. Such an approach would need to rely of the use of biomarkers since relying on symptoms might be too late.
Several biomarkers of risk for schizophrenia have been identified although none of them is sufficiently sensitive or specific, and therefore, further research is necessary to establish their predictive value (Lawrie et al. 2001; Johnstone et al. 2005; Sorensen et al. 2006; McGorry 2014) . Neurocognitive testing (Pukrop et al. 2007) , structural brain imaging (Wood et al. 2008) , and both conventional ) and quantitative (van Tricht et al. 2014 ) analyses of EEG have been used independently to differentiate individuals at risk for psychosis who will transition to psychosis from those who will not. While it is out of the scope of this paper to review all the approaches, we provide some examples of these approaches. Meta-analyses of clinically high risk (CHR) for psychosis individuals revealed that they had small to medium impairments in a wide range of neurocognitive domains (Woodberry et al. 2008; Giuliano et al. 2012) and that transition to psychosis is particularly associated with deficits in verbal fluency and memory functioning (Fusar-Poli et al. 2012) . Single-subject structural imaging using support vector (Bechdolf et al. 2012) Cognitive therapy (Morrison et al. 2002 (Morrison et al. , 2007 The prognostic score showed sens-88.9 % and spec-82.5 %.
Three risk classes establishing a prognostic index. In the class with the worst social-personal adjustment and lowest P300 amplitudes, the PPV was 74 %. machines has been gaining ground in separating schizophrenia from affective disorders and for the identification of individuals at high risk for psychosis (Koutsouleris et al. 2015) . Multivariate analysis of neuroanatomical patterns using support vector machines has been applied to classify subjects atrisk mental state (ARMS) for psychosis who transitioned to psychosis (Koutsouleris et al. 2009 ). Quantitative EEG analyses in the European Prediction of Psychosis Study categorized CHR subjects into three risk classes with the class III having a significantly higher hazard rate compared to risk classes I and II (van Tricht et al. 2014 ). More recently, attempts to improve predictive accuracy have used combinations of behavioral, cognitive, electrophysiological, structural, and functional neuroimaging data (Table 2 ). For example, combining negative symptoms with EEG power in the theta band correctly classified 89 % of ARMS who transitioned to psychosis (Zimmermann et al. 2010 ). These advances in refining the prediction of transition to psychosis in individuals who have already been identified as high risk based on the presence of subthreshold psychotic symptoms are important. However, there remains a critical need to identify those at high risk even earlier than the prevailing approaches allow, i.e., before the emergence of psychotic symptoms. The development of more sensitive and specific approaches applied to both the earliest detection of risk for schizophrenia in the general population and the prediction of conversion in high-risk individuals might alter the risk-benefit ratio in favor of psychosocial and pharmacological interventions directed toward individuals with the highest risk for schizophrenia.
Could the development of CST as a tool for early detection of CAD inform the development of a similar strategy for schizophrenia?
Cardiac stress testing (CST) has revolutionized the early detection and management of CAD and prevention of MI. Schizophrenia is a complex disorder that shares some similarities with CAD including the existence of modifiable (e.g., drug use) and non-modifiable (e.g., genetics) risk factors. Existing screening programs identify vulnerable populations primarily based on family history of schizophrenia or attenuated psychotic symptoms, which is analogous to relying on family history of CAD or symptoms (chest pain) to identify those at risk for CAD. Currently, a prerequisite for a diagnosis of schizophrenia is the occurrence of a psychotic (American Psychiatric Association 2000) . This is similar to diagnosing CAD after the occurrence of a MI and is too late for most preventive measures. As stated by Thomas Insel (2010) in BRethinking schizophrenia,^BIf risk (for schizophrenia) is analogous to hyperlipidemia, prodrome comparable to angina, then psychosis can be thought of as myocardial infarction with frequent residual loss of function.B elow, herewith, we briefly review the evolution of CST from its inception into its current form with a view toward informing the development of a similar approach for schizophrenia.
Cardiac stress testing refers to tests focused on stressing an individual's cardiovascular system through either physical exercise, pharmacological stimulation, or both so as to unmask compromised coronary circulation. Coronary hypoperfusion manifests as chest pain or discomfort and alterations in heart rate, blood pressure, and EKG-parameters that are monitored throughout the test. As CST has evolved over the years, physical exercise protocols have been standardized and newer and more sensitive markers of coronary hypoperfusion are being used. This has made CST more sensitive and specific for CAD and has improved the safety of testing (Gibbons et al. 2002) .
The evolution of CST from a research to a clinical tool
The clinical utility of CST has been greatly enhanced by the refinement of the stimulus parameters, outcome measures, and risk stratification of the patients who undergo CST. Before the 1930s, CST was used primarily as a research tool and its clinical use in diagnosing latent myocardial ischemia was first proposed around 1950 by Wood et al. (1950) and Hecht (1949) . Bruce proposed the stratification of patients into New York Heart Disease Classification groups I-IV based on criteria established by treadmill CST (Bruce et al. 1963 ). This was followed by the demonstration that the predictive value of ST segment depression for future coronary events was even higher than the predictive value of clinical history (Robb and Marks 1967) . In the ensuing years, several groups (Balcon et al. 1968; Najmi et al. 1968; Lewis and Wilson 1971; Martin and McConahay 1972 ) demonstrated a correlation between coronary angiographic data, which is the gold standard for confirming CAD diagnosis, and ST segment changes during CST. Formal guidelines have specified indications and contraindications for the test, interpretations of the results, risk stratification, and indications for termination (Fletcher 1997; Gibbons et al. 1997) .
Development and refinement of stimuli for CST
The initial stimulus for CST was relatively crude-patients were required to perform sit-ups while their symptoms and vital signs were monitored (Feil 1928) . This was followed by individualization of the exercise load to meet each patient's capacity (Wood et al. 1950) , the development of the 9-in. step (Missal 1938) , the use of the treadmill or bicycle (Northridge et al. 1990) , and standardized exercise protocols like the Bruce protocol (Bruce et al. 1963; Taylor et al. 1955 Taylor et al. , 1963 . Pharmacological agents, e.g., dipyramidole (Iskandrian et al. 1988) , dobutamine (Mason et al. 1984) , and adenosine (Nguyen et al. 1990) , to stress the cardiovascular system are being increasingly used, especially when performance of a conventional exercise test is impractical.
Development and refinement of outcomes for CST Self-reported outcomes In the early years, the outcome measures used in CST were almost exclusively composed of selfreports of subjective effects: chest pain or discomfort. Given the high predictive value of chest pain, the emergence of chest pain during CST was also an endpoint.
Objective outcomes The recognition that exercise-induced hypoperfusion in CAD patients was associated with ST segment depression on the EKG and with chest pain was pivotal in adopting an objective outcome-a biomarker. Riseman introduced the concept of continuous EKG monitoring that led to the recognition that ST segment depression preceded the onset of pain and persisted beyond the duration of pain (Riseman et al. 1940) . Since then, imaging techniques like thallium scintigraphy which measure cardiac perfusion and echocardiography which measures ventricular function have been developed and incorporated into CST and are now used in the calculation of the risk for CAD. Accordingly, the American Heart Association guidelines (Gibbons et al. 1997 ) stated that interpretation of the CST should include objective outcomes of exercise capacity (distance traversed, incline), changes in vital signs (e.g., blood pressure, heart rate), EKG (e.g., ST segment depression), coronary perfusion (scintigraphy), cardiac function (echocardiogram), etc. The nuclear stress test is generally considered to be the most accurate type of stress test with a specificity of ∼81 % and sensitivity of ∼90 %.
Over time, with the wide implementation of CST, the use and quantification of specific outcome measures and their value in predicting CAD have become well defined.
The target population for CST
The population at risk for CAD is stratified based on several clinical parameters including demographic information, symptoms (e.g., chest pain), family history of CAD and related risks, and current medical history and laboratory tests (Diamond and Forrester 1979) into low-, intermediate-, and high-risk categories. CST has the greatest utility in diagnosis and prognosis of CAD in individuals identified as having intermediate risk for CAD, i.e., in individuals who have angina but have not had an MI yet (prodromal symptoms but no psychotic episode). However, the American Heart Association (AHA) guidelines (Fletcher et al. 2013 ) recommend the use of CST also in individuals who have risk factors for CAD but have not had developed angina yet (risk factors but no prodromal symptoms). This process of identification of the population that would benefit greatest from CST has taken time and importantly, has involved updating the risk stratification as newer risk factors have been recognized.
CST has high negative and positive predictive values for cardiac events after the occurrence of MI. For example, following an MI, the negative predictive value (NPV) for another MI and cardiac death was 98.8 % over 36 months of follow-up for myocardial perfusion imaging and 98.4 % over 33 months for echocardiography (Metz et al. 2007) . A positive stress echocardiogram was associated with a threefold increased incidence of any cardiac event and a fourfold increased incidence of MI within 12 months of follow-up compared with a negative stress echocardiogram (Krivokapich et al. 1993) . Of note, these tests were performed in a population that had a high pretest probability of developing an MI. While CST may indeed confirm diagnosis in these already symptomatic individuals, it would not contribute to the prevention of CAD in this population. Furthermore, the true value of CST in the prevention of CAD lies in the identification of individuals who, while at risk, have not yet manifested angina. For example, in the Seattle Heart Watch Study, men with ≥1 risk factor (positive family history, smoking, hypertension [blood pressure >140/ 90 mmHg], and hypercholesterolemia [total cholesterol >240 mg/dL]) and two abnormalities on exercise testing (chest pain, exercise 1.0 mm, or 1 mm of ST depression on exercise testing had a 5.7 times greater risk of death from CAD than those with a negative test. In the Multiple Risk Factor Intervention Trial, retrospective analyses using the ST/HR index found a nearly fourfold increase in the 7-year rate of death from CAD among men with an abnormal test response and suggested that the exercise ECG might serve to identify high-risk men who do benefit from interventions targeting risk factor reduction. Therefore, in asymptomatic men >40 years of age with ≥1 risk factor, exercise testing could provide useful information as a guide to aggressive risk factor intervention (Bruce et al. 1980) .
In addition to the above, CST may also be useful in measuring the functional capacity of patients with established heart disease. In patients with CAD, CST may help assess the functional significance of partial blockages. If, during CST, signs of ischemia occur at a low level of exercise, the blockages could be presumed to be very significant, and conversely, if ischemia occurs only at high levels of exercise or does not occur at all, the blockages are likely to be much less significant.
The safety of CST
Major complications of exercise testing include hemodynamic instability, arrhythmia, MI, and rarely death. The rates of mortality due to CST were from 1.7 to 1 per 10, 000 in data collected prior to 1971 (Rochmis and Blackburn 1971) . However, over the last three decades, the improvement and standardization of techniques have further reduced the morbidity and mortality associated with CST (Gibbons et al. 2002) . Thus, more recent estimate of serious complications (including myocardial infarction and other events requiring hospitalization) in subjects with and without known disease is 1-5 per 10,000 tests, with death estimated to occur in ≈0.5 per 10,000 tests (Rodgers et al. 2000; Stuart and Ellestad 1980) . The reduced morbidity and mortality associated with CST have been attributed to several reasons, some of which have direct relevance to the development of PST including the following:
1. Identification of absolute and relative contraindications to testing (e.g., acute recent MI, acute myocarditis and pericarditis, uncontrolled cardiac arrhythmia); 2. Absolute and relative indications for aborting testing (Bstopping rules^) (e.g., ST segment elevation of more than 1 mm; moderate to severe angina, signs of poor perfusion, e.g., emergence of arrhythmias); 3. Identification and selection of safe stimuli; 4. Standardized procedures for testing; 5. Standardization of necessary safety equipment (e.g., emergency kit of and DC defibrillator) to be available during testing; 6. Standardization of intervention protocols to manage adverse events (reversal w ith nitroglycerin administration).
Limitations of CST
CST can only facilitate the diagnosis of obstructive CAD, in which the plaques cause significant obstruction to blood flow. However, there could be plaques that do not obstruct blood flow significantly but could rupture leading to the formation of a thrombus eventually obstructing the coronary artery and leading to an MI. Thus, CAD could also be associated with a Bnormalŝ tress test (false negative). Another major limitation of CST is that for it to be positive, the coronary arteries need to be occluded by 65 % or more. This limitation applies to all forms of CST because all the outcomes (EKG, echocardiogram or radioimaging) still depend upon there being a limitation of blood flow to the myocardium.
What CST unmasks
CST is based on the principle that application of stress to a compromised system allows a latent abnormality to be revealed. Thus, the application of physical exercise, pharmacological stimulation, or both, CST unmasks the consequence of plaque formation, i.e., coronary hypoperfusion. The latter manifests as physical symptoms and alterations in vital signs and/or EKG and is predictive of MI. CST does not reveal the primary pathophysiology of CAD, i.e., plaque, but rather unmasks the consequences of plaques, i.e., coronary hypoperfusion. Thus, CST is clinically useful even though it does not reveal the primary pathophysiology of CAD (Fig. 1) . By analogy, a stress test designed to unmask the risk for schizophrenia might do so by manifesting the consequences of the underlying pathophysiology without revealing the precise pathophysiology (Fig. 2) . This point is important given that the precise pathophysiology of schizophrenia remains elusive, and thus, its elucidation might not be a necessary prerequisite to developing a screening test that is clinically useful. Table 3 outlines how CST can inform the development of a potential PST and draws parallels between the stimuli, outcome measures, and clinical applications. The proposed stimuli, outcome measures, and clinical application of a potential PST are discussed below.
Projected development of stimuli for psychosis stress testing
It is expected that the development and refinement of PST into a clinically useful tool will be an iterative process. A number of factors should be considered in the development of ideal stimuli for PST (Table 4 ). The ideal stimulus would be one that confers PST with high sensitivity, specificity, PPV, and NPV in identifying individuals at risk. An ideal stimulus for PST should also have the following properties: (1) measurable dose, (2) uniform delivery, (3) good dose-response, (4) repeatability, (5) good test-retest reliability, and (6) good safety and tolerability. Furthermore, a preferred stimulus would be one that is known to be experienced by the population being tested outside of testing conditions-like physical exertion for CST.
Psychosocial stress stimuli, e.g., the Trier Social Stress Test (Kirschbaum et al. 1993 ) and the Montreal Imaging Stress Test (Pruessner et al. 2004) , can induce transient psychological stress in healthy subjects as well as patients with schizophrenia and individuals with a family history of psychosis. Such stress paradigms would have great acceptability because the stress induced is modest, transient, and well tolerated. However, these stimuli are difficult to quantify and dose, have limited repeatability, and may not elicit a large enough or specific enough response to identify risk of schizophrenia.
Pharmacological stimuli offer some advantages over psychological stimuli such as measurable dose, uniform delivery method, measurable dose-response, and repeatability. Ketamine (Krystal et al. 1994; Malhotra et al. 1996 Malhotra et al. , 1997 Parwani et al. 2005 ) delta-9-tetrahydrocannabinol (THC) (D'Souza et al. 2004 (D'Souza et al. , 2005 , dopaminergic agonists (Angrist et al. 1980 (Angrist et al. , 1982 Laruelle et al. 1995) , m-chlorpiperazine (Iqbal et al. 1991; Krystal et al. 1993) , iomazenil (Ahn et al. 2011) , psilocybin (Vollenweider et al. 1998) , salvinorin A , and N,N-dimethyltryptamine (Strassman et al. 1994 ) have been administered to healthy individuals and/or those with schizophrenia. In the few studies that have investigated these drugs in populations at risk for psychosis (Abi-Dargham et al. 2004; Egerton et al. 2013; Henquet et al. 2006; Howes et al. 2011) , the goal has been to characterize neurotransmitter abnormalities, e.g., dopamine agonists to study dopamine function. Hence, thus far, psychological and pharmacological stimuli have been directed toward studying the pathophysiology of schizophrenia and not for the early detection and risk stratification of individuals at risk (D'Souza et al. 1999) .
Projected development of outcome measures for PST
Putative stimuli for PST can induce transient mood changes, perceptual alterations, and a range of psychosis-like effects (Angrist et al. 1980; Hope et al. 1951; Janowsky et al. 1973; Lieberman et al. 1987; Pennes 1954; Simon and Taube 1946) that can be captured using self-reported measures such as the Visual Analog Scales (VAS) and the Psychotomimetic State Inventory (PSI) (Mason et al. 2008 ) and also clinician-rated measures such as the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962) , Positive and Negative Syndrome Scale (PANSS) (Kay et al. 1987) , and Clinician Administered Dissociative Symptoms Scale (CADSS) (Krystal et al. 1994) . Objective outcomes include cognitive testing (verbal memory, working memory, attention, and executive function (Morgan and Curran 2006; Ranganathan and D'Souza 2006) , electrophysiological indices of information processing (p50 (Light et al. 1999; Vollenweider et al. 2007 ), p300 , gamma oscillations (Cortes-Briones et al. 2015a), cortical noise (Cortes-Briones et al. 2015b ) and mismatch negativity (Umbricht et al. 2002) ), and brain imaging (positron emission tomography (Egerton et al. 2013; Vollenweider et al. 1997; Wolkin et al. 1987) , single-photon emission computerized tomography (Laruelle et al. 1996) , functional magnetic resonance imaging (fMRI) (Anticevic et al. 2012; Corlett et al. 2013; Driesen et al. 2013) , and magnetic resonance spectroscopy (Stone et al. 2012) ). While those at risk might show abnormalities in these measures at baseline, a PST might magnify these changes to a level that might help differentiate risk more conclusively. These measures will need to be tested in suitable target populations with a wide range of risk and also for their sensitivity to the proposed stimuli used in PST to determine their suitability as target outcome measures.
The target population for PST
An iterative process may be expected in refining the group who would benefit most from a PST. Thus, PST may be most Psychotic disorders Individuals at high risk for psychosis on the basis of family history of psychosis, attenuated psychotic symptoms, or schizotypy score high on at-risk measurement scales. Preexisting psychotic illness. More will need to be identified with the development, experience, and refinement of this approach. Early diagnosis of the risk for psychosis and early intervention for primary prevention of psychosis. Transient: anxiety, psychotic symptoms, cognitive impairment, mood changes Persistent: psychosis Table 4 Characteristics of pharmacological agents as putative stressors for psychosis stress test ↑Positive, negative and cognitive symptoms (Krystal et al. 1994) ↑Positive, negative and cognitive symptoms (D'Souza et al. 2004) Little or no increase in positive symptoms (Ahn et al. 2011) Alterations in mood, thought, perception, and self-experience (Studerus et al. 2011) Acute effects in schizophrenia patients ↑Positive symptoms (Angrist et al. 1980) ↑Positive, negative and cognitive symptoms (Lahti et al. 2001; Malhotra et al. 1997; Malhotra et al. 1996) ↑Positive, negative and cognitive symptoms ( Nausea/vomiting Symptom-related distress (Carpenter 1999; Lahti et al. 1995) Nausea, vomiting, tachycardia, anxiety Anxiety, lowered seizure threshold
Anxiety and panic-like reactions
Exposure of general population to the stimulus/recreational use of stimulus low low High (over 50 % over 12th graders)
Low to none Low useful in identifying individuals who, while at risk, have not yet manifested symptoms of psychosis for which a population with a wide range of risk for schizophrenia would need to be studied. Table 1 lists risk factors that could potentially assist in identification of a population that would benefit from a PST. Finally, the development of a suitable PST must consider the risk/benefit profile of the approach.
Safety of PST
As with CST, in order for PST to become a clinically useful tool, safe stimuli need to be identified and the absolute and relative contraindications to testing, the testing parameters, the indications for aborting testing, and the protocols for managing adverse events need to be operationalized.
That the outcome measures for CST are EKG changes, perfusion abnormalities or chest pain, and not myocardial infarction confers a favorable risk/benefit profile for CST. Similarly, the proposed outcome measures for PST would need to be signs or symptoms proximal to full-blown psychosis and not the latter for it to be acceptable. The currently proposed stimuli and outcome measures for PST meet this threshold. Further, as discussed above, development of a PST will require identification of parameters and guidelines for termination of testing as well as provision for rescue medications.
A proposed PST stimulus-the example of cannabinoids
As an initial step toward identifying a suitable stimulus for PST, taking into account the favorable profile of existing pharmacological stimuli, we suggest that cannabis or its primary active component THC may offer some advantages over others. First, exposure to cannabis is widespread; it is by far the most commonly used illicit drug worldwide especially among young adults, who would be the target population for a PST. For instance, in the USA, the rate of lifetime exposure to cannabis among 12th graders is almost 50 % (Johnston et al. 2014) . Furthermore, the rates of cannabis use in individuals at risk for psychosis are high. For example, in the North American Prodrome Longitudinal Study (NAPLS), 30 % of the controls and 40 % of the clinical high-risk sample rated themselves as current users of cannabis (Addington et al. 2012) . Furthermore, with the growing legalization of medical and recreational cannabis across the USA (Bly 2012; Kleber and Dupont 2012; procon.org) , it is conceivable that exposure to cannabis in the population could increase. Thus, the proposed stimulus is one that the target population has likely been exposed to. Second, relevant to psychosis, the recreational use of cannabis has been linked to transient psychosis-related outcomes; i.e., the stimulus is related to the outcome of interest. Thus, in laboratory studies, cannabinoids (THC and nabilone) can induce acute, transient psychosis-related outcomes in healthy subjects and exacerbate psychosis in individuals with schizophrenia (D'Souza et al. 2005; Radhakrishnan et al. 2014) . Furthermore, distinct from these acute effects, epidemiological studies suggest an association between cannabis exposure in adolescence and later psychosis outcomes including schizophrenia (Radhakrishnan et al. 2014) . Third, related to safety, while not completely without risk, laboratory studies with THC have been well tolerated and are not associated with psychosis beyond the test day in healthy individuals with and without a family history of psychosis (Henquet et al. 2006) and even in patients with established schizophrenia (D'Souza et al. 2005) . In a review of the safety of THC in controlled laboratory conditions in 266 subjects, there was one serious and 70 minor adverse events in 9.7 % of subjects. Nausea and dizziness were the most frequent side effects. Of 149 subjects on whom long-term follow-up data (up to 1 year) were gathered, 94 % reported either no change or a reduction in their desire to use cannabis in the post-study period . The effects of THC or cannabis have also been studied in individuals with psychosis liability as defined by a family history of psychosis or psychometrically (a threshold score on the Schizotypal Personality Questionnaire) (Henquet et al. 2005 (Henquet et al. , 2006 Verdoux et al. 2003) . It is reasonable to assume that the acute risks of a PST in individuals at risk for psychosis will fall somewhere in between healthy individuals and individuals with an established psychotic disorder. Thus, the most likely risks of PST observed in healthy adults and adults with psychotic disorders or risk of psychosis are transient and spontaneously reversible psychotic symptoms (not disorder), anxiety, and cognitive deficits. This begs the question, are the risks of CST comparable to the risks of PST? For example, how do the risks of a commonly used pharmacological cardiac stress test, the dobutamine stress test, compare to the effects of THC in the laboratory? According to the AHA Bcomplications of dobutamine infusion include nausea, headache, tremor, anxiety, angina and atypical chest pain, atrial and ventricular arrhythmias, and hypertension or hypotension. MI (<0.02 %) and death (<0.002 %) as complications are very rare.^As compared to this, during THC infusions, we have encountered minor side effects such as nausea and headache in <2 % subjects ) and hypertension in one subject with preexisting hypertension. Fourth, THC offers advantages over psychological stressors in having greater specificity in inducing psychosis-relevant outcomes in addition to possessing repeatability, test-retest reliability, uniform dosing, and predictable dose-response. A comparison of THC with other putative pharmacological stimuli is presented in Table 4 .
Existing data on THC suggest that it could possess an acceptable risk-benefit profile as a PST stimulus. While most existing data is on THC-induced behavioral effects, recent studies have examined its effects on schizophrenia-relevant electrophysiological and neurocognitive biomarkers. For example, THC has been shown to reduce P300 amplitude ) and auditory mismatch negativity (Juckel et al. 2007) , disrupt gamma oscillations (CortesBriones et al. 2015a) , and increase cortical noise (CortesBriones et al. 2015b ) measured in EEG. The use of such biomarkers may permit developing a PST using a dose of THC low enough to minimize significant distress. Further testing may help determine contraindications for PST, e.g., individuals with existing acute psychotic symptoms, past history of severe psychotic reactions, etc. Stopping rules for PST need to be operationalized and may include an increase in psychosislike symptoms beyond a predetermined threshold (e.g., >30 % PANSS score increase) and/or in subjective distress. Rescue procedures (e.g., lorazepam; extended observation) will need to be operationalized.
The acceptance of PST
For PST to be of any value, it would need to be done before or during the window of vulnerability. The latter is typically from adolescence to young adulthood. Society has much lower thresholds of what is unacceptable in adolescents vs. adults. Interestingly, while CST is typically done in adults, it may not be well known that it is also routinely used in children too, for the evaluation of cardiac disease (Ghosh et al. 2015; Washington et al. 1994) . The AHA has a position statement about stress testing in children and adolescents (Paridon et al. 2006) with (1) guidelines for how to obtain consent for CST from the parent and assent from the child, (2) equipment requirements, (3) indications and contraindications for stress testing, (4) indications for exercise testing termination, and (5) protocols for testing. While there is limited data on the safety of CST in children and adolescents, it is not devoid of clinical significant risks including arrhythmias and, in theory, death.
The acceptance of a PST will depend on the benefit realized by earlier discovery of a psychotic disorder, balanced by any negative consequences. Furthermore, the value of a PST will depend on the effectiveness of the existing treatment interventions. Having curative treatments would make the value of a PST very high. However, curative treatments for psychotic disorders do not exist. In fact, there are few curative disorders for most chronic medical and psychiatric conditions. In some instances, as is the case with Alzheimer's disease (AD), while existing treatments do not change the ultimate course of the disease, some approaches could slow the process of AD, especially when used early in the course of the disease. Or, in the case of psychotic disorders, managing psychosis with antipsychotics drugs can alter outcome through a number of pathways without necessarily altering the pathophysiology of the disorder. Detecting a psychotic disorder earlier may provide the impetus to develop treatments that arrest or slow the disease process beyond what is offered by existing antipsychotic treatment. Finally, PST may be more acceptable and justified if the stressor stimulus is one that is commonly encountered by many people similar to physical exertion and CST.
The feasibility and acceptance of screening of children and adolescents for other disorders are relevant to the development of a psychosis stress test. The World Health Organization commissioned Wilson and Jungner (1968) to develop criteria to guide the selection of conditions that would be suitable for screening tests. The criteria have been challenged and revised and are presented (Table 5) to provoke discussion about how these apply to PST. Applying these criteria for PST, there is enough to make the case for developing and testing a PST as a screening tool for psychotic disorders.
Pitfalls of psychosis stress testing
The most significant problems associated with any screening test are the problems of false positives and negatives, which PST will undoubtedly associated with. In fact, the adverse effects from false-positive or false-negative test results with CST for CAD are estimated to have a greater negative impact than the risks associated with the tests themselves (Arbab-Zadeh 2012). If 25 % of those who are false positive undergo cardiac catheterization, they would be exposed to the chance of a major complication (1.7 %) including MI, stroke, or even death. If a person is wrongly diagnosed (false positive) with a psychotic disorder, he/she may be subjected to unnecessary stigma, shame, and treatment. The individual and the family may have to endure unnecessary stress caused by the belief (erroneous) of having a life-long, incurable disorder. A false-negative result could give rise to a false sense of security, and treatments that could alter disease course could be delayed. The rates of false-positive and false-negative cases of a psychotic disorder will only become evident with time.
Challenges
While there are numerous attractive possibilities in applying lessons learned from CST to the detection of risk for or conversion to psychosis, there are several limitations that need to be acknowledged and taken into account in the development of PST.
First, if schizophrenia is an assortment of disorders caused by varying pathophysiologies that is currently viewed as a single disorder, it is possible that a single stimulus/test will not have sufficient sensitivity or specificity. Nevertheless, as discussed earlier, if there is some final common pathway to the expression of ischemia, then CST is useful regardless of the primary pathophysiology, i.e., plaque, vasospasm, or inflammation. Extrapolating this to psychotic disorders, if there is some common final pathway to psychosis, then regardless of the different primary pathophysiologies (as yet unknown), PST might still be useful.
Second, the lifetime prevalence of CAD has been estimated by the Centers for Disease Control to be 6 % while the lifetime prevalence of schizophrenia is lower. Thus, the PPV of any PST is likely to be low. However, it should be noted that the estimated prevalence of CAD in those aged 18-44 years by the CDC is 1.2 %-comparable to schizophrenia. Furthermore, if a PST is to screen for psychotic disorders in general including bipolar disorder and schizoaffective disorder, then the cumulative rates of these disorders are even higher.
Third, Bstate^factors such as recent stress, fatigue, insomnia, anxiety, and substance use may influence the outcome measures on the PST and lead to false positives. However, similar factors may apply to CST but have not negated its usefulness. Fourth, vulnerable individuals who might be candidates for PST may have a greater incidence of mood and anxiety disorders, substance use, and personality disorders even in the absence of a psychosis, all of which could impact the outcomes of the PST.
Conclusions
The history of evolution of CST may guide the development of a similar approach for the detection and management of There should be quality assurance, with mechanisms to minimize potential risks of screening.
?
Could be developed
The program should ensure informed choice, confidentiality, and respect for autonomy.
+
The program should promote equity and access to screening for the entire target population.
?
This would be easier to do in nationalized health systems
Program evaluation should be planned from the outset. Could be developed
The overall benefits of screening should outweigh the harm. Not clear Needs to be determined There should be an agreed policy on whom should be treated ? To be developed The cost of case finding should be economically balanced in relation to possible expenditure on medical care as a whole ? To be assessed. In the long run, early discovery may result in lower direct and indirect costs of disease burden Case finding should be a continuing process and not a Bonce and for all^project + Adapted from the World Health Organization (see Wilson and Jungner 1968) psychotic disorders. Current approaches for detecting the risk for or conversion to psychosis in high-risk individuals rely on the presence of attenuated positive symptoms which is analogous to diagnosing CAD after the occurrence of angina or MI. Similar to CST, the initial development of a test to unmask latent risk for schizophrenia will require the selection of a suitable and safe stimulus and the development of outcome measures as a prelude to testing in populations with a range of risk to determine predictive value. The use of CST in CAD offers the intriguing possibility that a similar approach may be applied to the detection and management of schizophrenia.
